Tech Mahindra Secures Multiple Awards at the 2025 Pharmaceutical Technology Excellence Awards
Tech Mahindra has been recognized with the Safety, Research and Development, and Innovation awards at…
Newswire
BioMarin to Acquire Rare Disease Drugmaker Amicus for $4.8B
BioMarin Pharmaceutical has announced its acquisition of Amicus Therapeutics for $4.8 billion, a strategic move…
BioMarin to pay $4.8B for Amicus and its rare disease drugs
BioMarin plans to dish out $4.8 billion to acquire Amicus Therapeutics and its two approved…
Altimmune Advances to Phase 3 in MASH Following Previous Trial Setback
Altimmune has announced its advancement to Phase 3 trials for pemvidutide, a GLP-1/glucagon agonist aimed…
MHRA Approves Lenacapavir for the Prevention of Sexually Transmitted HIV-1 Infection
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for lenacapavir, marking…
Transforming US drug access and production: MFN pricing deals and historic manufacturing investments
In November 2025, US President Donald Trump announced transformative actions aimed at lowering prescription drug…
Nxera Seeks Schizophrenia Programme Buyer After Boehringer Snub
Shares in Tokyo-listed Nxera Pharma slid 5% at market open following Boehringer Ingelheim’s decision to…
Filovirus Detection by Immune System Improved by Nanoparticle Vaccine
Researchers at Scripps Research have developed a novel nanoparticle vaccine that enhances the immune system’s…
Galapagos TYK2 Drug Achieves Success in Dermatology Trial but Falls Short in Lupus Study
The Belgian biotech Galapagos has reported mixed results for its TYK2 inhibitor, GLPG3667, achieving success…
AI and Gene Therapy Lead 2025’s Most Impactful Pharma Stories
In a year marked by significant advancements, the final episode of 2025 from the GEN…